{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T22:35:03Z","timestamp":1773268503864,"version":"3.50.1"},"reference-count":94,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T00:00:00Z","timestamp":1494288000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Patients infected with human immunodeficiency virus (HIV) admitted to the hospital have complex antiretroviral therapy (\n                      <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content>\n                      ) regimens with an increased medication error rate upon admission. This report provides a resource for clinicians managing\n                      <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\n                      \u2010infected patients and\n                      <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content>\n                      in the inpatient setting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A survey of the authors was conducted to evaluate common issues that arise during an acute hospitalization for\n                      <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\n                      \u2010infected patients. After a group consensus, a review of the medical literature was performed to determine the supporting evidence for the following\n                      <jats:styled-content style=\"fixed-case\">HIV\u2010<\/jats:styled-content>\n                      associated hospital queries: admission\/discharge orders, antiretroviral hospital formularies, laboratory monitoring, altered hepatic\/renal function, drug\u2010drug interactions (\n                      <jats:styled-content style=\"fixed-case\">DDI<\/jats:styled-content>\n                      s), enteral administration, and therapeutic drug monitoring.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      With any hospital admission for an\n                      <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\n                      \u2010infected patient, a specific set of procedures should be followed including a thorough admission medication history and communication with the ambulatory\n                      <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\n                      provider to avoid omissions or substitutions in the\n                      <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content>\n                      regimen. DDIs are common and should be reviewed at all transitions of care during the hospital admission. ART may be continued if enteral nutrition with a feeding tube is deemed necessary, but the entire regimen should be discontinued if no oral access is available for a prolonged period. Therapeutic drug monitoring is not generally recommended but, if available, should be considered in unique clinical scenarios where antiretroviral pharmacokinetics are difficult to predict. ART may need adjustment if hepatic or renal insufficiency ensues.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Treatment of hospitalized patients with\n                      <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\n                      is highly complex.\n                      <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\n                      \u2010infected patients are at high risk for medication errors during various transitions of care. Baseline knowledge of the principles of antiretroviral pharmacotherapy is necessary for clinicians managing acutely ill\n                      <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\n                      \u2010infected patients to avoid medication errors, identify\n                      <jats:styled-content style=\"fixed-case\">DDI<\/jats:styled-content>\n                      s, and correctly dose medications if organ dysfunction arises. Timely ambulatory follow\u2010up is essential to prevent readmissions and facilitate improved transitions of care.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/phar.1921","type":"journal-article","created":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T15:02:43Z","timestamp":1488985363000},"page":"611-629","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Acute Care Management of the\n                    <scp>HIV<\/scp>\n                    \u2010Infected Patient: A Report from the\n                    <scp>HIV<\/scp>\n                    Practice and Research Network of the American College of Clinical Pharmacy"],"prefix":"10.1002","volume":"37","author":[{"given":"Spencer H.","family":"Durham","sequence":"first","affiliation":[{"name":"Department Pharmacy Practice Auburn University Harrison School of Pharmacy Auburn Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa E.","family":"Badowski","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Pharmacy Practice University of Illinois at Chicago, College of Pharmacy Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle D.","family":"Liedtke","sequence":"additional","affiliation":[{"name":"Department of Clinical and Administrative Sciences, College of Pharmacy University of Oklahoma Health Sciences Center Oklahoma City Oklahoma"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Chris","family":"Rathbun","sequence":"additional","affiliation":[{"name":"Department of Clinical and Administrative Sciences, College of Pharmacy University of Oklahoma Health Sciences Center Oklahoma City Oklahoma"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Pecora Fulco","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Virginia Commonwealth University Health Richmond Virginia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,5,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/003335491412900212"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)30087-X"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp150623"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1758-2652-12-1"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014534195"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K547"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1716"},{"key":"e_1_2_11_9_1","unstructured":"Hospital: 2016 national patient safety goals. The Joint Commission. November 5 2015. Available fromwww.jointcommission.org\/hap_2016_npsgs\/. Accessed August 1 2016."},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080552"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/61.16.1689"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.4140\/TCP.n.2013.775"},{"key":"e_1_2_11_13_1","unstructured":"Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV\u20101\u2010infected adults and adolescents. Department of Health and Human Services. Available fromhttp:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf. Accessed June 23 2016."},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328311d16f"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3281c61394"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013607"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005575"},{"key":"e_1_2_11_18_1","unstructured":"Panel on Opportunistic Infections in HIV\u2010Infected Adults and Adolescents.Guidelines for the prevention and treatment of opportunistic infections in HIV\u2010infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention the National Institutes of Health and the HIV Medicine Association of the Infectious Diseases Society of America. Available fromhttp:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adult_oi.pdf. Accessed November 15 2016."},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-3-200302040-00007"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1370\/afm.1753"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1086\/672271"},{"key":"e_1_2_11_22_1","unstructured":"Centers for Disease Control and Prevention.Updated guidelines for antiretroviral postexposure prophylaxis after sexual injection drug use or other nonoccupational exposure to HIV\u2014United States 2016. Available fromhttp:\/\/www.cdc.gov\/hiv\/pdf\/programresources\/cdc-hiv-npep-guidelines.pdf. Accessed July 16 2016."},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.8900"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit004"},{"key":"e_1_2_11_25_1","first-page":"37","article-title":"Renal complications in HIV disease: between present and future","volume":"14","author":"Maggi P","year":"2012","journal-title":"AIDS Rev"},{"key":"e_1_2_11_26_1","first-page":"144","article-title":"Novel antiretroviral drugs and renal function monitoring of HIV patients","volume":"16","author":"Maggi P","year":"2014","journal-title":"AIDS Rev"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04440.x"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182645648"},{"key":"e_1_2_11_29_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/760706","article-title":"HIV antiretroviral therapy induced liver, gastrointestinal and pancreatic injury","volume":"760706","author":"Neuman MG","year":"2012","journal-title":"Int J Hepatol"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800600817"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000958"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00211-8"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000908"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077268"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.3.355"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis621"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh684"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1590-9"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f0e2fd"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528010-00004"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-6405-7-32"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1086\/313912"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1086\/341084"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1086\/421386"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000243103.03265.2b"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.142452"},{"key":"e_1_2_11_47_1","unstructured":"Gilead Sciences.Descovy (emtricitabine; tenofovir alafenamide fumarate) package insert.Foster City CA;2016."},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199804303381808"},{"key":"e_1_2_11_49_1","unstructured":"Gilead Sciences.Tybost (cobicistat) package insert.Foster City CA;2016."},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000219774.20174.64"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740330903493458"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.5.898"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122009728"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903176446"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e328356e91c"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000630"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000983"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00636-10"},{"key":"e_1_2_11_59_1","unstructured":"RamanathanS ShenG HinkleJ EnejosaJ KearneyB.Pharmacokinetic evaluation of drug interactions with ritonavir\u2010boosted HIV integrase inhibitor GS\u20109137 (elvitegravir) and acid\u2010reducing agents (Abstract 69). 8th International Workshop on Clinical Pharmacology of HIV Therapy Budapest Hungary April 16\u201318 2007."},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr139"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03198.x"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014523115"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016655427"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.025257"},{"key":"e_1_2_11_65_1","unstructured":"American Association for the Study of Liver Diseases\u2010Infectious Diseases Society of America.HCV guidance: recommendations for testing managing and treating hepatitis C. Available fromwww.hcvguidelines.org. Accessed September 28 2016."},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp120106"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp140575"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1835"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540120701767182"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/PHAR.1015"},{"key":"e_1_2_11_71_1","first-page":"39","article-title":"Orogastric administration of crushed darunavir tablets for a critically ill patient","volume":"67","author":"Kim CH","year":"2014","journal-title":"Can J Hosp Pharm"},{"key":"e_1_2_11_72_1","unstructured":"Gilead Sciences.Truvada (emtricitabine; tenofovir disoproxil fumarate) package insert.Foster City CA;2016."},{"key":"e_1_2_11_73_1","unstructured":"Bristol\u2010Myers Squibb.Sustiva (efavirenz) package insert.Princeton NJ;2016."},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31820eefbe"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp120772"},{"key":"e_1_2_11_76_1","unstructured":"ViiV Healthcare.Tivicay (Dolutegravir) package insert.Research Triangle Park NC;2016."},{"key":"e_1_2_11_77_1","unstructured":"Merck & Company Inc.Isentress (Raltegravir) package insert.Whitehouse Station NJ;2015."},{"key":"e_1_2_11_78_1","unstructured":"ColbersA deHoonM vanCrevelR et al.Pharmacokinetics of crushed elvitegravir combination tablet given with drip feed (Poster 431). Conference on Retroviruses and Opportunistic Infections Boston MA February 22\u201325 2016."},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328348fc41"},{"key":"e_1_2_11_80_1","unstructured":"ViiV Healthcare.Lexiva (fosamprenavir) package insert.Research Triangle Park NC;2016."},{"key":"e_1_2_11_81_1","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1093\/ajhp\/57.14.1332","article-title":"Development of an indinavir oral liquid for children","volume":"57","author":"Hugen PWH","year":"2000","journal-title":"Am J Health Syst Pharm"},{"key":"e_1_2_11_82_1","unstructured":"Hoffman LaRoche.Invirase (saquinavir) package insert.Nutley NJ;2016."},{"key":"e_1_2_11_83_1","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc.Aptivus (tipranavir) package insert.Ridgefield CT;2008."},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.55.6777"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.48.1906"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1179\/1973947813Y.0000000140"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp130597"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200301030-00023"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014525034"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt084"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31821b42d1"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2878"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.1002\/PHAR.1003"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12339"},{"key":"e_1_2_11_95_1","first-page":"341","article-title":"Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of patients infected with human immunodeficiency virus and related health care costs: a real\u2010life study in a large cohort of patients","volume":"6","author":"Perrone V","year":"2014","journal-title":"Clinicoecon Outcomes Res"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1921","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1921","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:44:15Z","timestamp":1761068655000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":94,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1002\/phar.1921"],"URL":"https:\/\/doi.org\/10.1002\/phar.1921","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"2017-05-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}